N-(4-phenylbutanoyl)-1,2,3,6-tetrahydropyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-(4-phenylbutanoyl)-1,2,3,6-tetrahydropyridine
• 英文别名: 1-(3,6-dihydro-2H-pyridin-1-yl)-4-phenylbutan-1-one
• 化学式: C₁₅H₁₉NO
• 分子量: 229.32
• InChiKey: FZOSPHPRRROATJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-苯基丁酸 、 1,2,3,6-四氢吡啶 生成 N-(4-phenylbutanoyl)-1,2,3,6-tetrahydropyridine
  参考文献：
  名称：

  OGURA, KUNIESI;AOTSUKA, TOMOSI;TORITSUKA, MOTOKI;SOEHDA, MITSUO;TANAKA, J+

  摘要：

  DOI：

文献信息

• Phenylalkanoylamine derivatives, process for preparing the same, and
  申请人：Zeria Pharmaceutical Co., Ltd.

  公开号：US05198450A1

  公开（公告）日：1993-03-30

  An agent for treating or preventing cerebral circulation disorder, cerebral metabolism disorder, or memory disturbance is disclosed. The agent comprises as an effective component a phenylalkanoylamine derivative represented by the following formula (I), ##STR1## wherein A represents a 1,3-thiazolidin-3-yl group, a 1,2,3,6-tetrahydropyridin-1-yl group, a morpholino group, a thiomorpholin-4-yl group, or a 3-pyrrolin-1-yl group, R.sup.1 and R.sup.2, which may be the same or different, represent a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a nitro group, an amino group, a guanidino group, or a group ##STR2## (wherein R.sup.3 and R.sup.4 independently represent a lower alkyl group or form in combination 5- or 6-membered heterocyclic group), and n represents an integer of 2-6, or a salt thereof. This agent is effective for treating or preventing cerebral hemorrhage sequela, cerebral infarction sequela, cerebral arterioscleosis, subarachnoid hemorrhage sequela, cranial injury sequela, cerebral operation sequela, cerebrovascular dementia, Parkinson's disease, Alzheimer's disease, Pick's disease, various anoxia toxicosis including, but not limited to anthracemia sequela, cerebral alcoholism related diseases, and the like.

  本发明涉及一种用于治疗或预防脑循环障碍、脑代谢障碍或记忆障碍的药剂。该药剂包含以下式(I)所表示的苯基丙酰胺衍生物作为有效组分：其中，A代表1,3-噻唑啉-3-基、1,2,3,6-四氢吡啶-1-基、吗啉基、硫代吗啉-4-基或3-吡咯烷-1-基，R1和R2，可以相同也可以不同，分别代表氢原子、卤素原子、较低的烷基、较低的烷氧基、硝基、氨基、鸟氨酸基或##STR2##（其中R3和R4独立地代表较低的烷基或组成5-或6-成员杂环基），n代表2-6的整数，或其盐。该药剂对于治疗或预防脑出血后遗症、脑梗死后遗症、脑动脉硬化、蛛网膜下腔出血后遗症、头部损伤后遗症、脑手术后遗症、脑血管痴呆、帕金森病、阿尔茨海默病、皮克氏病、各种缺氧中毒症包括但不限于炭疽病后遗症、与酗酒相关的脑疾病等都具有良好的疗效。
• PHENYLALKANOYLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USES
  申请人：ZERIA PHARMACEUTICAL CO., LTD.

  公开号：EP0424528A1

  公开（公告）日：1991-05-02

  Drugs for improving cerebral circulation, cerebral metabolism and memory containing as the active ingredient a phenylalkanoylamine derivative or its salt represented by general formula (I) (wherein A represents a 1,3-thiazolin-3-yl group, a 1,2,3,6-tetrahydropyridin-1-yl group, a morpholino group, a thiomorpholin-4-yl group or a 3-pyrrolin-1-yl group, R¹ and R² may be the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a nitro group, an amino group or (α) (wherein R³ and R⁴ each represents a lower alkyl group or, when taken together, they represent a 5- or 6-membered heterocyclic group together with the nitrogen atom), and n represents an integer of 2 to 6) and novel phenylalkanoylamine derivatives among the compounds represented by (I), and a process for their preparation are disclosed. The above drugs are useful for treating sequelae of cerebral hemorrhage, sequelae of cerebral infarction, arterial aclerosis of brain, sequelae of subarachnoidal hemorrhage, sequelae of head trauma, sequelae of cerebral operation, dementia of cerebral vessel origin, Parkinson's disease, Alzheimer's disease, Pick's disease, sequelae of hypoxia, alcoholic cerebral diseases, etc.

  改善脑循环、脑代谢和记忆的药物，其活性成分含有通式(I)代表的苯基烷酰基胺衍生物或其盐(其中A代表1,3-噻唑啉-3-基、1,2,3,6-四氢吡啶-1-基、吗啉基、硫代吗啉-4-基或3-吡咯啉-1-基，R¹和R²可以相同或不同，各自代表氢原子、(α)（其中 R³ 和 R⁴ 各自代表一个低级烷基，或当它们结合在一起时，与氮原子一起代表一个 5 或 6 元杂环基团），且 n 代表 2 至 6 的整数）和(I)所代表的化合物中的新型苯基烷酰基胺衍生物及其制备方法。上述药物可用于治疗脑出血后遗症、脑梗塞后遗症、脑动脉硬化、蛛网膜下腔出血后遗症、头部外伤后遗症、脑手术后遗症、脑血管源性痴呆、帕金森病、阿尔茨海默病、皮克病、缺氧后遗症、酒精性脑病等。
• US5198450A
  申请人：——

  公开号：US5198450A

  公开（公告）日：1993-03-30